The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
In an interview with CancerNetwork®, Peter Voorhees, MD, of the Levine Cancer Institute, spoke about findings from an updated analysis of the Phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
What we show with this updated analysis is that the rates of stringent [complete response (CR] continue to improve and clearly favor the daratumumab (Darzalex) arm. So, looking at stringent CR in the daratumumab arm, we're now up to 63.6% with one year of maintenance therapy, in contrast to 47.4% for those in the control arm and this is highly statistically significant. If we look at all complete responses stringent to non-stringent, it's close to 82% in the daratumumab compared to close to 61% in the control arm. When we look at MRD negativity, measured with [next generation sequencing] at a sensitivity level of 10-5 in the intent to treat analysis, the [minimal residual disease (MRD)] negative rate in the daratumumab arm is 62 and a half percent in contrast to 27% for those in the control arm. If we look at those patients specifically who have MRD evaluable disease, the rates of MRD negativity in the experimental arm of the daratumumab arm is 78%, in contrast to 39.5% in the control arm.